The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1422
August 5, 2013
View Complete Issue         Table of Contents 2019 
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
August 5, 2013 (Issue: 1422)
The FDA has approved two new oral kinase inhibitors for treatment of unresectable or metastatic melanoma: dabrafenib (Tafinlar – GSK) for melanomas with BRAF V600E mutations and trametinib (Mekinist – GSK) for melanomas with either BRAF V600E...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dabrafenib (Tafinlar) and Trametinib (Mekinist) for Metastatic Melanoma
Article code: 1422b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.